Detalhe da pesquisa
1.
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.
Blood
; 141(3): 219-230, 2023 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36095849
2.
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma.
Cancer
; 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38630908
3.
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 22(1D): e240001, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38244272
4.
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Cancer
; 129(23): 3746-3760, 2023 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37622738
5.
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 21(12): 1281-1301, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38081133
6.
Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
Cancer
; 127(22): 4198-4212, 2021 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34314018
7.
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Lancet Oncol
; 21(2): 207-221, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31859245
8.
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Blood
; 130(8): 974-981, 2017 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-28637662
9.
Role of bone-anabolic agents in the treatment of breast cancer bone metastases.
Breast Cancer Res
; 16(6): 484, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25757219
10.
Tumor-expressed adrenomedullin accelerates breast cancer bone metastasis.
Breast Cancer Res
; 16(6): 458, 2014 Dec 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-25439669
11.
A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma.
Blood
; 120(22): 4324-33, 2012 Nov 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-23033266
12.
1q amplification and PHF19 expressing high-risk cells are associated with relapsed/refractory multiple myeloma.
Nat Commun
; 15(1): 4144, 2024 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38755140
13.
Cancer Surveillance in Solid Organ Transplant Recipients With a Pretransplant History of Malignancy: Multidisciplinary Collaborative Expert Opinion.
Transplantation
; 2024 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38771067
14.
Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma.
Blood Cancer J
; 13(1): 144, 2023 09 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37696786
15.
Identifying 1q amplification and PHF19 expressing high-risk cells associated with relapsed/refractory multiple myeloma.
Res Sq
; 2023 Aug 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37645789
16.
GFI1-Dependent Repression of SGPP1 Increases Multiple Myeloma Cell Survival.
Cancers (Basel)
; 14(3)2022 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35159039
17.
The novel histone deacetylase inhibitor, AR-42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells.
Int J Cancer
; 129(1): 204-13, 2011 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20824695
18.
DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
Adv Ther
; 38(11): 5501-5518, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34561812
19.
Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis.
Expert Rev Hematol
; 14(12): 1137-1145, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34465265
20.
Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma.
Br J Haematol
; 150(3): 313-25, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20560971